Nurse Practitioner Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Kimberly Smarsh

Nurse Practitioner Marco Island, FL Nurse Practitioner

NPI 1669050076 CMS profile 10763295

606 Bald Eagle Dr Ste 302, Marco Island, FL 34145

Open in the dashboard

General payments

$2,848

130 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kimberly Smarsh of Marco Island, FL is reported in the CMS Open Payments database as having received $2,848 across 130 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $639 32
2024 General $917 37
2023 General $813 38
2022 General $480 23

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kimberly Smarsh
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Kimberly Smarsh were reported at $639. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Kimberly Smarsh Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $0 $135 $40–$426 $132
2022 $480 $152 $48–$470 $149
2023 $813 $166 $54–$529 $160
2024 $917 $173 $55–$556 $164
2025 $639 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Boston Scientific Corporation $347 9 payments
  2. Merck Sharp & Dohme Corporation $297 12 payments
  3. Radius Health, Inc. $237 11 payments
  4. Janssen Pharmaceuticals, Inc $204 9 payments
  5. Exact Sciences Corporation $198 7 payments
  6. Amgen Inc. $195 11 payments
  7. Pfizer Inc. $172 10 payments
  8. AstraZeneca Pharmaceuticals LP $165 10 payments
  9. GlaxoSmithKline, LLC. $137 8 payments
  10. Lilly USA, LLC $136 8 payments
  11. Other $760 35 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $2,848 130 payments
Products named General payments · program years 2022–2025
  1. GARDASIL 9 $297 12 payments
  2. WATCHMAN FLX $287 7 payments
  3. VAXNEUVANCE $210 8 payments
  4. XARELTO $204 9 payments
  5. PNEUMOVAX 23 $169 7 payments
  6. Tymlos $164 8 payments
  7. Cologuard Collection Kit $148 5 payments
  8. PROQUAD $147 6 payments
  9. EVENITY $137 8 payments
  10. ELIQUIS $131 8 payments
  11. Other $2,648 132 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 102 drugs

Part D claims

4,974

Median for Nurse Practitioner: 389

Drug cost

$285,666

Median for Nurse Practitioner: $21,885

Branded share of claims

15.5%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 37 $58,147
Jardiance Empagliflozin Brand 38 $49,199
Mounjaro Tirzepatide Brand 26 $38,645
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 26 $27,685
Xarelto Rivaroxaban Brand 13 $21,136
Myrbetriq Mirabegron Brand 14 $11,307
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 12 $9,919
Synthroid Levothyroxine Sodium Brand 56 $4,372
Rosuvastatin Calcium Generic 334 $3,845
Estradiol Generic 42 $2,660

The 10 drugs with the highest cost, of 102 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 81 billing codes

Paid by Medicare

$212,406

Of which drugs: $7,188

Medicare patients

849

Average age 77

Services billed

8,310

674 women, 175 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 69%
Arthritis 58%
Depression 34%
Osteoporosis 32%
Ischemic heart disease 27%
Chronic kidney disease 22%
Atrial fibrillation 19%
COPD 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 59 59 $4,817
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 21 21 $19

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XARELTO
  • Janssen Pharmaceuticals, Inc $61
$61 13 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $51
$51 — —
Auvelity
  • Axsome Therapeutics, Inc. $31
$31 — —
PAXLOVID
  • PFIZER INC. $29
$29 26 —
ELIQUIS
  • PFIZER INC. $27
$27 37 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

130 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record